Evaluation of different measles IgG assays based on recombinant proteins using a panel of low-titre sera

被引:12
作者
Hartter, HK
de Swart, RL
Hanses, F
Vos, HW
Bouche, FB
Osterhaus, ADME
Schneider, F
Muller, CP
机构
[1] Lab Natl Sante, Dept Immunol, L-1011 Luxembourg, Luxembourg
[2] Lab Natl Sante, WHO Collaborating Ctr Measles, L-1011 Luxembourg, Luxembourg
[3] Univ Tubingen, Fac Med, Tubingen, Germany
[4] Erasmus Univ, Inst Virol, Rotterdam, Netherlands
[5] Lab Natl Sante, Dept Microbiol, Luxembourg, Luxembourg
关键词
measles; IgG antibodies; ELISA; neutralisation assay; haemagglutination assay; flow cytometry;
D O I
10.1016/S0166-0934(99)00143-3
中图分类号
Q5 [生物化学];
学科分类号
071010 ; 081704 ;
摘要
During the WHO campaign to eradicate measles, accurate discrimination between immune and non-immune individuals will become increasingly important. Due to waning immunity in vaccinated populations, the performance of a measles Ige assay depends mainly on its ability to detect reliably seronegative individuals among many vaccinees with low antibody levels. New serological tests based on recombinant proteins detect only a fraction of the total measles virus (MV) specific antibodies. Therefore, several assays based on recombinant MV-haemagglutinin (ELISA and flow cytometry) or MV-fusion protein (flow cytometry) as well as neutralisation and haemagglutination test have been evaluated using a large panel of low-titre and negative sera. Since such an evaluation is highly dependent on threshold values for positivity, the receiver operating characteristic curve analysis was applied. The H-FACS and the H-ELISA showed the best performing characteristics (specificity: 97.4 and 96.1%, respectively; sensitivity: 88.1 and 89.6%, respectively) and may be an alternative to the neutralisation assay. The number of undefined/grey zone sera was significantly lower compared to a commercial whole virus-based ELISA and therefore fewer individuals would be vaccinated unnecessarily. (C) 2000 Elsevier Science B.V. All rights reserved.
引用
收藏
页码:191 / 200
页数:10
相关论文
共 39 条
[31]   DIFFERENCES IN APPEARANCE OF ANTIBODIES TO STRUCTURAL COMPONENTS OF MEASLES-VIRUS AFTER IMMUNIZATION WITH INACTIVATED AND LIVE VIRUS [J].
NORRBY, E ;
ENDERSRUCKLE, G ;
TERMEULEN, V .
JOURNAL OF INFECTIOUS DISEASES, 1975, 132 (03) :262-269
[32]  
Paunio M, 1998, AM J EPIDEMIOL, V148, P1103, DOI 10.1093/oxfordjournals.aje.a009588
[33]   COMPARISON OF COMMERCIAL ENZYME-IMMUNOASSAY KITS WITH PLAQUE REDUCTION NEUTRALIZATION TEST FOR DETECTION OF MEASLES-VIRUS ANTIBODY [J].
RATNAM, S ;
GADAG, V ;
WEST, R ;
BURRIS, J ;
OATES, E ;
STEAD, F ;
BOUILIANNE, N .
JOURNAL OF CLINICAL MICROBIOLOGY, 1995, 33 (04) :811-815
[34]   COMPUTER-ASSISTED RAPID ENZYME-LINKED IMMUNOSORBENT-ASSAY (ELISA) IN THE SEROLOGICAL DIAGNOSIS OF ASPERGILLOSIS [J].
RICHARDSON, MD ;
TURNER, A ;
WARNOCK, DW ;
LLEWELLYN, PA .
JOURNAL OF IMMUNOLOGICAL METHODS, 1983, 56 (02) :201-207
[35]   ROC CURVES AND THE AREAS UNDER THEM FOR DICHOTOMIZED TESTS - EMPIRICAL-FINDINGS FOR LOGISTICALLY AND NORMALLY DISTRIBUTED DIAGNOSTIC-TEST RESULTS [J].
VANDERSCHOUW, YT ;
STRAATMAN, H ;
VERBEEK, ALM .
MEDICAL DECISION MAKING, 1994, 14 (04) :374-381
[36]   Effect of subclinical infection on maintaining immunity against measles in vaccinated children in West Africa [J].
Whittle, HC ;
Aaby, P ;
Samb, B ;
Jensen, H ;
Bennett, J ;
Simondon, F .
LANCET, 1999, 353 (9147) :98-102
[37]  
*WHO, 1998, MMWR-MORBID MORTAL W, V47, P1049
[38]  
*WHO, 1997, MMWR-MORBID MORTAL W, V46, P1
[39]  
*WHO, 1977, MMWR-MORBID MORTAL W, V46, P766